summari report sale
organ came ahead estim
consensu expect growth led
rtg restor therapi group mitg minim
therapi group help off-set soft cardiac vascular
group cvg diabet non-gaap ep ex-
fx well-abov consensu estim
though wed note like aid part lower btl below-
the-lin expens street model guidanc
front introduc fiscal guidanc includ organ
sale growth /- guid organ growth
manag note top-lin growth expect
closer /- north back-half
year anticip acceler driven time new
product launch y/i comp dynam also note
expect top-lin momentum build fiscal
comment four divis potenti see
growth acceler bottom-lin introduc
report ep guidanc ex-fx
includ anticip headwind fx
compar previou consensus/our prior estim
ep mdt report ep guidanc includ
fx hit pictur manag remain confid
compani pipelin upcom product launch drive growth
topic announc host investor day fall
unveil surgic robot platform first time street
remain track commerci launch fiscal
chang model increas fiscal sale estim
organ increas fiscal
non-gaap ep estim report
maintain price target base
cy ep estim
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort reflect combin follow
acquisit cov
compani data secur llc estim reuter
 recap revenu organ came ahead estim
consensu growth better guidanc /-
report ep ex-fx ahead consensu estim
ep upsid vs model mostli reflect higher revenu lower net interest expens vs
estim lower opex vs estim partli off-set lower gross
margin vs estim
revenu divis cardiac vascular group cvg sale organ ahead
consensu in-lin estim minim invas therapi group mitg revenu
grew organ ahead consensu in-lin forecast restor
therapi group rtg sale increas organ ahead consensu
forecast diabet revenu rose organ miss consensu
meet forecast
crhf growth remain challeng mdt crhf cardiac rhythm heart failur sale fell
compar high power growth
implant cardiovert defibril declin mid-singl digit global primarili due us
crt-d cardiac resynchron therapi defibril global sale fall estim yr/yr
low power ww pacemak slightli crt-p cardiac resynchron therapi
pacemak sale low-doubl digit mdt af atrial fibril solut grew
mid-teen consist continu uptak arcticfront cryoballoon diagnost
sale growth acceler mid-teen mid-singl digit reveal linq deliv
strongest growth two year
hope share lvad continu lose share lvad left ventricular
assist devic sinc sale declin high ww us
growth headwind mdt lvad busi includ competit abt dt destin
therapi us approv recent chang guidelin depriorit
heart transplant patient lvad bridge-to-transpl popul howev
compani expect return offens posit smaller hvad system emphas
lower complic rate favor stroke data believ recaptur share
lvad market model modest share gain lvad model hvad
csh growth led tavr csh coronari structur heart revenu grew organ
modest deceler growth csh growth larg driven transcathet aortic
valv replac tavr growth includ wed note compar ew
ww tavr growth ex-fx includ growth estim note
pleas low-risk trial result american colleg cardiolog meet
march yet seen meaning benefit data separ de drug elut stent
declin mid-single-digit global basi
apv growth slow due dcb drug-coat balloon headwind apv aortic
peripher vascular sale grew organ slower growth
quarter reflect high-singl digit declin dcb sale due paclitaxel headwind note
dcb sale declin rang us ou growth partli off-set on-going
launch japan remain confid admir safeti data head june fda adcom
compani note data dcb trial japan inpact deep knee critic
limb ischemia show higher mortal rate pta percutan translumin angioplasti arm
compar dcb arm like competitor also assum fda current stanc dcb use
recommend altern remain post-panel declin dcb part
off-set growth taa continu roll valiant navion
pain franchis stabl sequenti global pain therapi segment sale
y/i ex-fx growth consist level pain stim deliv above-
market growth gain share y/i basi estim return leadership posit
year accord driven combin intelli evolv workflow
snapshot report estim ww spinal cord stimul sale ex-
fx includ us use mdt result estim global
market flat ex-fx meaning slowdown vs level estim us
like grew msd similar driven strength verterbroplasti look ahead
look launch accurian nerv ablat platform aid growth
spine grew modestli global spine sale y/i ex-fx
rel flat y/i growth deliv result driven strength spine especi
cervic biolog product line core spine deliv first posit quarter
growth sinc driven recent launch product infin oct solera voyag
increas mazorx attach rate result lsd growth slightli higher us versu
ou versu lsd declin post sequenti quarter notabl spine sale growth combin
enabl technolog report neurosurgeri within brain divis post sequenti
acceler includ us result
suggest combin portfolio gain traction compani surgic synergi strategi
worth highlight percentag mazor robot case use spine implant
double-digit sequenti bmp bone morphogenet protein sale
deceler sequenti us declin lsd versu lsd msd growth
off-set hsd growth intern market consist
brain therapi grew double-digit brain therapi sale grew consist
growth solid growth momentum led high-teen growth neurovascular mid-
teen growth neurosurgeri within neurosurgeri saw growth capit equip
sale driven stealthstat navig mazor robot o-arm imag compani see
signific runway ahead continu growth mazor stealth edit robot guidanc platform
sold mazor system increas spine robot share compani
continu see mazor sale good lead indic futur growth core spine busi
fact estim system sold part combin capit
implant contract mazor robot case use spine implant neurovascular
note strength broad stroke portfolio includ continu double-digit growth stent retriev
flow divert neuro-access coil product manag highlight recent refresh product
offer includ new solitair stent retriev relaunch riptid aspir system
react aspir cathet estim hold share us aspir
market target share end ultim market share higher
share assumpt report high-teen growth ww neurovascular busi
report growth neurovascular busi includ estim growth
stroke expect continu strong growth overal stroke market translat solid
growth momentum key player
specialti therapi sale growth acceler global specialti therapi segment sale
y/i ex-fx growth acceler rel level sequenti
acceler appear broad-bas includ ent hsd versu msd transform
solut high-teen versu mid-teen pelvic health flat versu msd
mitg growth slow somewhat mitg sale total growth compar
surgic innov si sale grew
si perform reflect slower growth momentum advanc
advanc stapl advanc energi sale grew high singl digit vs low-doubl digit growth
continu driven ligasur valleylab mdt advanc energi busi continu
outperform competitor jnj energi segment grew vs due strength
aspac offset continu share loss us advanc stapl grew mid-singl digit vs
high-singl digit help tri-stapl signia power stapler similarli jnj
endocutt sale grew improv low-singl digit growth stronger ou
perform led aspac report low-singl digit growth gener surgeri strength
wound closur comparison jnj gener surgeri sale flat yr/yr includ growth
wound closur busi part driven market growth us aspac respiratori
gastrointestin renal sale growth slow
slower growth seen across busi respiratori grew market low-
singl digit vs high single-digit continu strength puritan bennett ventil
growth gi solut slow low-singl digit mid-singl digit solid perform
diagnost region mitg sale growth led emerg market vs
us non-u develop market sale fell yr/yr vs
surgic unveil fall investor meet launch track
medtron robot assist surgeri ra platform remain track commerci launch
april manag indic platform launch oversea first like india
note first time plan unveil system investor event fall entir event
dedic robot platform includ direct feedback surgeon user new
updat encourag impli platform closer commerci recal last quarter
indic held sever submiss meet regulatori bodi around
world includ fda surgeon alreadi use platform manag continu
expect fairli modest revenu contribut greater contribut
diabet growth continu slow due tough y/i comparison global diabet sale
segment sale growth y/i driven difficult y/i comparison us pump sale
competit pressur unit state segment advanc insulin manag sale growth
deceler sequenti lsd versu msd emerg technolog et grew
y/i vs growth aim sale impact difficult y/i comparison us
competit pressur somewhat off-set growth integr cgm on-going launch
minim oversea compani note see increas cgm penetr within
instal base healthi pace new patient acquisit benefit launch guardian sensor
minim pump patient emea off-set difficult comp us pump backlog
resolv oversea compani continu experi strong demand minim
instal base grew y/i sequenti final et sale driven fourth
consecut quarter tripl digit sale growth guardian connect cgm system look ahead
expect diabet growth re-acceler accret total compani growth
full fiscal year growth expect aid launch next-gen minim
compani also plan file non-inject indic cgm sensor earli would
allow access us medicar market
post anoth quarter double-digit em growth emerg market em revenu
y/i ex-fx compar growth manag note strong em growth
across busi multipl geographi region south asia grew fastest ex-fx
follow southeast asia middl east/africa china
europ latin america grew overal em revenu account
revenu in-lin estim large-cap med-tech median em exposur mdt em growth
ex-fx also in-lin large-cap med-tech median growth rate china
note continu expect double-digit growth region despit headwind tariff
increas manag character manag headwind margin
outlook mostli in-lin expect growth acceler expect earlier today
provid initi fiscal organ sale growth guidanc /- expect
fx headwind impli report revenu rang /-
mdt sale outlook busi follow cvg expect grow /- mitg expect
grow /- rtg expect grow /- diabet expect grow
/- addit manag guid growth note top-lin growth
expect closer /- north back-half year anticip
acceler driven time new product launch y/i comp dynam also note
expect top-lin momentum build fiscal comment four divis
potenti see growth acceler regard margin laid oper
margin improv target ex-fx basi compar mdt long-rang plan
lrp goal annual bottom-lin manag guid non-gaap ep
compar consensus/our previou estim guidanc impli
non-gaap ep growth ex-fx basi note expect hit fx
ep mdt report ep guidanc includ fx hit
larg cap med-tech organ growth declin modestli report thursday
morn aggreg growth rate larg cap med-tech name see figur
analysi indic world-wide organ ex-fx growth y/i compar
growth stack two-year basi healthi compar
figur
note organ growth adjust fx acquisitions/divestitur sell day meaning
note organ growth adjust fx acquisitions/divestitur sell day meaning
organ growthfi med-tech pf cfn average excl growth year stack med-tech pf cfn average excl medic technolog
price target nc
price target assum cy cash ep estim risk includ
weak key end market greater share loss model delay product launch
believ deliv averag organ growth due lull major new product launch
combin competitor headwind
found minneapolis-bas lead global medic technolog compani
focus provid therapi chronic diseas compani four primari busi cardiac
vascular restor therapi minim invas therapi diabet revenu
plc incom statementin million except per share datafisc year end etot net currenc y-i expensesresearch oper incomenet interest expens amort incom tax incom adj continu year-to-year incom year-to-year incom dilut share year-to-year compani report secur llc estim plc
